A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma

Giuseppe Todeschini(University of Pisa), Giovanni Pizzolo(Fondazione IRCCS Istituto Nazionale dei Tumori), Cristina Tecchio(University of Verona), Daniela Dalceggio(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), A. Gabbas, Massimiliano Bonifacio(University of Verona), Fabio Benedetti(Azienda Ospedaliera Universitaria Integrata Verona)

Hematological Oncology

September 27, 2010

10.1002/hon.966

Cited by 0

Related Papers

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

|The Lancet|2018|733

ALK+ lymphoma: clinico-pathological findings and outcome.

|PubMed|1999|569

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

|Blood|2008|253

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

|The Lancet|2023|194

Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma

|Journal of Clinical Oncology|2010|167